WESTLAKE VILLAGE, Calif., April 12, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. ARQTan early-stage commercial company focused on developing significant innovations in immunodermatology, today announced that Arcutis management will attend an upcoming investor conference.
Details of the company’s participation are as follows:
- 22nd Annual Needham Virtual Healthcare Conference
Fireside Chat Date: Tuesday April 18, 2023
Fireside chat time: 11:45 a.m. ET
The webcast for this conference can be found at “eventssection of the company’s website. The webcast replay will be available on the Arcutis website for 90 days after the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. ARQT is an early commercial-stage medical dermatology company committed to meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving dermatology’s most intractable patient challenges, Arcutis has a growing portfolio that leverages our unique dermatology development platform coupled with our dermatology expertise to develop differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline of multiple clinical programs across a range of inflammatory dermatological conditions, including scalp and body psoriasis, atopic dermatitis, seborrheic dermatitis and alopecia areata. For more information visit www.arcutis.com or follow Arcutis on LinkedIn, FacebookAnd Twitter.
Forward-Looking Statements
This press release contains “forward-looking” statements, including, without limitation, statements regarding the potential to meet urgent needs and expectations regarding the timing of data and regulatory events. These statements involve significant known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievements…
[ad_2]
Source story
